Achim Moesta

Achim Moesta is a Vice President and Head of Immunology and Translational Sciences at Trishula Therapeutics. Achim’s responsibilities are currently focused on the advancement of TTX-030 in clinical development.

Prior to joining Trishula, Achim was the Head of Immunology Discovery and Translational Sciences at Tizona Therapeutics where he spearheaded several novel immune modulatory biologic programs and oversaw both TTX-030 and TTX-080, a first-in-class HLA-G antagonist, from inception to Phase 1 clinical trials.

Achim previously held roles of increasing responsibility at Amgen in the Therapeutic Innovation Unit and Oncology Discovery Research. Additionally, Achim was a postdoctoral fellow at the Pfizer-Rinat Biotherapeutics innovation hub.

Achim earned his Ph.D. in Immunology from Stanford University under Dr. Peter Parham, a world leader in Immunogenetics and the functional interactions of Natural Killer Cells.